Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: Distinct from multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 3, 2013, Pages 289-298

  Quan, Chao ^a   Yu, Hai ^a   Qiao, Jian ^a   Xiao, Baoguo ^a,b   Zhao, Guixian ^a   Wu, Zhiying ^a,b   Li, Zhenxin ^a   Lu, Chuanzhen ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

autoimmunity; B cell activating factor; CXCL13; multiple sclerosis; Neuromyelitis optica; regulatory B cells

Indexed keywords

AQUAPORIN 4 ANTIBODY; B CELL ACTIVATING FACTOR; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; VERY LATE ACTIVATION ANTIGEN 4;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84874361447     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512454771     Document Type: Article

References (35)

1. Kira J, Yamasaki K, Horiuchi I, et al. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci. 1999 ; 166: 53-57
2. Kira J.. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003 ; 2: 117-127
3. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 ; 53: 1107-1114
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis opica: distinction from multiple sclerosis. Lancet. 2004 ; 364: 2106-2112
5. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011 ; 74: 1-13
6. Roemer SF, Parisi JE, Lennon VA, et al. Pattern specific loss of aquaporin 4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007 ; 130: 1194-1205
7. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006 ; 63: 390-396
8. Hauser SL, Waubant E, Arnold DL. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Eng J Med. 2008 ; 358: 676-688
9. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011 ; 68: 1412-1420
10. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology. 2008 ; 70: 2252-2260
11. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006 ; 129: 200-211
12. Kalinowska-Łyszczarz A, Szczuciński A, Pawlak MA, et al. Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients. J Neurol Sci. 2011 ; 300: 81-85
13. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009 ; 73: 2003-2010
14. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011 ; 17: 335-343
15. Zhong X, Wang H, Dai Y, et al. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol. 2011 ; 240-241: 104-108
16. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005 ; 201: 195-200
17. Thangarajh M, Gomes A, Masterman T, et al. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol. 2004 ; 152: 183-190
18. Okada K, Matsushita T, Kira J, et al. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology. 2010 ; 74: 177-178
19. Vaknin-Dembinsky A, Brill L, Orpaz N, et al. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult Scler. 2010 ; 16: 1453-1457
20. Knopf PM, Harling-Berg CJ, Cserr HF, et al. Antigendependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigenspecific B cells. J Immunol. 1998 ; 161: 692-701
21. Duddy M, Niino M, Adatia F. Distinct effector cytokine profiles of memory and naïve human B cell subsets and implication in multiple sclerosis. J Immunol. 2007 ; 178: 6092-6099
22. Lund FE. Cytokine-producing B lymphocytes - key regulators of immunity. Curr Opin Immunol. 2008 ; 20: 332-338
23. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010 ; 6: 326-327
24. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol. 2007 ; 29: 34-39
25. Blair PA, Norena LY, Flores-Borja F. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010 ; 32: 129-140
26. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005 ; 58: 840-846
27. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
28. Carsetti R, Rosado MM, Wardemann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004 ; 197: 179-191
29. Hirotani M, Niino M, Fukazawa T, et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol. 2010 ; 221: 95-100
30. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009 ; 9: 491-502
31. Piazza F, DiFrancesco JC, Fusco ML, et al. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J Neuroimmunol. 2010 ; 220: 104-107
32. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity. 2001 ; 14: 377-386
33. Brettschneider J, Czerwoniak A, Senel M, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS ONE. 2010 ; 5: e11986
34. Kim SM, Waters P, Vincent A, et al. Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. J Neurol. 2011 ; 258: 2176-2180
35. Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011 ; 18: 1313-1317